US 11,052,072 B2
Pyrazolo[4,3-C] quinoline derivatives for inhibition of β-glucuronidase
Yeh-Long Chen, Kaohsiung (TW); Tian-Lu Cheng, Kaohsiung (TW); Cherng-Chyi Tzeng, Kaohsiung (TW); Chih-Hua Tseng, Kaohsiung (TW); Ta-Chun Cheng, Kaohsiung (TW); Kai-Wen Cheng, Kaohsiung (TW); and Wei-Fen Luo, Kaohsiung (TW)
Assigned to KAOHSIUNG MEDICAL UNIVERSITY, Kaohsiung (TW)
Filed by Kaohsiung Medical University, Kaohsiung (TW)
Filed on Dec. 12, 2019, as Appl. No. 16/711,623.
Application 16/711,623 is a division of application No. 15/577,201, previously published as PCT/US2016/034379, filed on May 26, 2016.
Claims priority of provisional application 62/166,322, filed on May 26, 2015.
Prior Publication US 2020/0113878 A1, Apr. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01); A61P 35/00 (2006.01); A61K 31/055 (2006.01); A61K 31/03 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 31/055 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01); A61K 31/03 (2013.01)] 4 Claims
 
1. A method for treating chemotherapy-induced diarrhea and for treating and/or reducing tumorigenesis of carcinogens induced colon carcinoma in a subject, comprising administering an effective amount of a compound of the following Formula I,

OG Complex Work Unit Chemistry
a pharmaceutical acceptable salt of the compound of the Formula I, or a solvate of the compound of the Formula I to a subject,
wherein R1 is H, and R2 is one of 4′-F and 4′-Me.